National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents.
about
Managing Patients With Psoriasis in the Busy Clinic: Practical Tips for Health Care PractitionersHepatic manifestations of non-steroidal inflammatory bowel disease therapyReview of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasisBiologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring.Biologic safety in psoriasis: review of long-term safety data.Biologics in dermatologic therapy - an update.Psoriasis, anti-tumor necrosis factor therapy, and tuberculosis: report of three challenging cases and literature review.Is There a Potential Role for Anti-tumor Necrosis Factor Therapy in Patients with Human Immunodeficiency Virus?The role of TNF inhibitors in psoriasis therapy: new implications for associated comorbidities.A practical approach to monitoring patients on biological agents for the treatment of psoriasisThe Challenging Evaluation of Patients with Severe Psoriasis for Latent Tuberculosis: An Important Indication for IGRA.Reactivation of Tuberculosis in Three Cases of Psoriasis after Initiation of Anti-TNF Therapy.Psoriatic disease and tuberculosis nowadays.Infliximab in patients with psoriasis and other inflammatory diseases: evaluation of adverse events in the treatment of 168 patients.An update on granulomatous diseases of the oral tissues.Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature.IFN-gamma release assays in tuberculosis management in selected high-risk populations.Clinical experience of QuantiFERON(®) -TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan.Ustekinumab for the treatment of psoriasis.Detection and management of latent tuberculosis infections before biologic therapy for psoriasis.Biologics in oral medicine: principles of use and practical considerations.Management of long-term therapy with biological drugs in psoriatic patients with latent tuberculosis infection in real life setting.[Medicinal prophylaxis during intensified immunosuppression in children and adolescents : part 2].British Association of Dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016.Prevalence of latent tuberculosis infection in patients with moderate to severe psoriasis taking biologic therapies in a dermatologic private practice in Miami, Florida.Association of clinical properties and compatibility of the QuantiFERON-TB Gold In-Tube test with the tuberculin skin test in patients with psoriasis.Latent tuberculosis infection in patients with chronic plaque psoriasis: evidence from the Italian Psocare Registry.Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis.Interferon-γ release assay for tuberculosis in patients with psoriasis treated with tumour necrosis factor antagonists: in vivo and in vitro analysis.Usefulness of QuantiFERON®-TB Gold test in psoriatic patients under treatment with tumour necrosis factor blockers.Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection.The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis.Safety of biologics in psoriasis.Erythrodermic psoriasis with regression after prophylaxis with isoniazid and antidepressant therapy: case report.The burden of psoriasis in Canada: insights from the pSoriasis Knowledge IN Canada (SKIN) survey.Choroidal tuberculoma in a patient with ocular Behçet disease.Screening and prevention for latent tuberculosis in immunosuppressed patients at risk for tuberculosis: a systematic review of clinical practice guidelines
P2860
Q26771785-2421BCD3-897F-4731-B86B-D19C314B867EQ26773684-5E169EFB-E257-45D3-998C-8B1C55C8606DQ28280687-BA4AC3EA-17BA-49CC-A068-E6CC86E8D1B3Q30412650-A2210AAA-DB9B-4782-B8BB-03A2874F10CBQ30904076-7837A961-7623-471F-8079-4C5D8EEFE9D3Q33607620-6072A856-9657-428C-BD1F-BBF06EEE0F18Q33939033-0F7ED44E-C103-4E0F-8121-0577D72EDFECQ34074149-C9E99B5F-39DC-42CE-A6DB-3DBEB8DDA8B4Q34076431-172EB9B8-37E4-4875-B04F-28D0B9B6AB27Q34156420-38C3D993-78F8-485F-8BF0-7321C6D93FF3Q35095293-F6A25FA8-6D9A-4264-B9B6-9A388D31568BQ35903142-A4C4B50C-172B-4C6E-8D78-08A598F3FD56Q35974892-62586998-6787-4D95-AC66-DC29A0C48BB6Q37078893-66F84C2F-EB57-49B5-A4E4-1C9A535D7A41Q37177491-168948E6-0DF3-4908-9B92-166A69731991Q37303223-15098B78-0A54-4D3B-AE30-910192BEFED5Q37418061-679B1AC5-16DF-4211-8BA7-E989DB712B38Q37810305-349BE7A8-4B15-44C0-A33A-B9929636C6E1Q37855945-6407E7BC-6157-4ADB-AC86-8689E34AD6D6Q37972320-836DAA7B-44F9-4321-BF08-1CD0EF1BE6C5Q37993932-A04C189D-F963-4952-A658-C6FED2A60C93Q40197638-0E1B465C-47E0-4098-8EA4-475F6511EC8FQ40238572-009EB83E-BAF2-422E-9C04-B911B05966BCQ40590985-8C9C0C00-6B3E-4D01-8883-041F2768C396Q40800468-788ADAB4-4B33-4996-8420-7042492B507BQ40938299-6D462A7A-5076-45DB-9B6B-5361FB0E7564Q41658983-80BB968E-551D-4C5A-9BD1-CE6A32E4FD6CQ41688405-0B38D795-2A10-446F-A8F7-EB7140EABEFBQ42252749-A05F0828-47D4-4172-9067-7750EB3516F9Q44024721-CC0BEAAD-48DC-4342-9688-0D5C3AF04289Q46247849-9DA39C32-928E-412E-9514-84377BEE2A54Q46758133-AF06314A-7352-4D81-9338-95082F52DE37Q47644680-5F7665D6-DAC5-4654-AABF-E4A07CC4FFB3Q48144965-5C29C0D9-B692-4A1B-90E0-C45D3504E78BQ48786883-FFA89B32-D300-4D8D-A66B-F032F9E44AF8Q49024262-F6D63FFA-1B75-42E5-BA17-870C71E57456Q51362406-5ADA0AA7-CEF0-4EA5-85AD-EADBE97A84D7Q58746309-F3812B5D-D113-4BB3-B9C6-C409F5623314
P2860
National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
National Psoriasis Foundation ...... systemic and biologic agents.
@en
National Psoriasis Foundation ...... systemic and biologic agents.
@nl
type
label
National Psoriasis Foundation ...... systemic and biologic agents.
@en
National Psoriasis Foundation ...... systemic and biologic agents.
@nl
prefLabel
National Psoriasis Foundation ...... systemic and biologic agents.
@en
National Psoriasis Foundation ...... systemic and biologic agents.
@nl
P2093
P1476
National Psoriasis Foundation ...... systemic and biologic agents.
@en
P2093
Abby Van Voorhees
Mark G Lebwohl
Melodie S Young
National Psoriasis Foundation
Neil J Korman
Sean D Doherty
Sylvia Hsu
P304
P356
10.1016/J.JAAD.2008.03.023
P407
P577
2008-05-15T00:00:00Z